What is HER2-targeted therapy?
HER2-targeted therapy is a group of cancer medicines that attack cancers with too much of a protein called HER2 (human epidermal growth factor receptor 2). HER2 sits on the surface of cells and passes on signals telling them to grow. In some cancers, the HER2 gene is copied many times over, so the cells are covered in HER2 and grow quickly.
About 15-20% of breast cancers are HER2-positive, and HER2 is also found in some stomach, oesophageal, bowel, salivary gland, lung and womb cancers. HER2-positive breast cancer was once linked with a poor outlook. Thanks to HER2-targeted drugs, it is now among the most treatable types.
The main drugs are trastuzumab (Herceptin), pertuzumab (Perjeta), the antibody-drug conjugates trastuzumab deruxtecan (T-DXd, Enhertu) and trastuzumab emtansine (T-DM1, Kadcyla), and tablets such as tucatinib, lapatinib and neratinib.
A brief history
The HER2 gene was identified in the 1980s, and researchers soon noticed that breast cancers with many copies of it tended to behave aggressively. This led to the development of trastuzumab, one of the first antibodies designed against a specific cancer target. It was approved for advanced breast cancer in 1998 and, after large trials such as HERA, became standard after surgery for early breast cancer in the mid-2000s.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of treatment | Targeted therapy: monoclonal antibodies, antibody-drug conjugates and kinase inhibitor tablets |
| Main uses | HER2-positive breast cancer; HER2-positive stomach and oesophageal cancer; HER2-low breast cancer (T-DXd) |
| How it is given | Drip into a vein or injection under the skin every 3 weeks; some drugs are tablets |
| Course length | About 1 year for early breast cancer; as long as it works for advanced cancer |
| Test needed | Tumour tested for HER2 (IHC and/or in situ hybridisation) |
| Main side effects | Heart function changes, diarrhoea, tiredness; lung inflammation with T-DXd |
| Monitoring | Heart scans (echocardiogram or MUGA) every few months |
2. How it works
The different drug types
| Drug | Type | How it works |
|---|---|---|
| Trastuzumab | Monoclonal antibody | Binds HER2, blocks its signal and marks the cell for attack by the immune system |
| Pertuzumab | Monoclonal antibody | Binds a different part of HER2, stopping it pairing with partner receptors |
| Trastuzumab emtansine (T-DM1) | Antibody-drug conjugate | Trastuzumab carrying a chemotherapy payload into HER2-positive cells |
| Trastuzumab deruxtecan (T-DXd) | Antibody-drug conjugate | Trastuzumab carrying a strong topoisomerase inhibitor; payload can also reach neighbouring cells |
| Tucatinib, lapatinib, neratinib | Kinase inhibitor tablets | Block the HER2 signal from inside the cell |
Why two antibodies work better than one
HER2 sends its strongest signals when it pairs with related receptors such as HER3. Trastuzumab and pertuzumab attach to different parts of the HER2 protein, so using both blocks signalling more completely. This dual blockade is now standard for many people with HER2-positive breast cancer.
Antibody-drug conjugates
An antibody-drug conjugate works like a guided missile. The antibody finds the cancer cell and the attached chemotherapy is released inside it. This delivers a strong dose to the cancer while limiting effects on the rest of the body. T-DXd’s payload can pass into nearby cells, which may explain why it also works in cancers with only low levels of HER2.
3. Who it is for
Conditions treated
| Condition | Role of HER2-targeted therapy |
|---|---|
| HER2-positive breast cancer | Before and after surgery, and for advanced disease |
| Invasive ductal carcinoma | When the tumour tests HER2-positive or HER2-low |
| Inflammatory breast cancer | Often HER2-positive; treatment given before surgery |
| Male breast cancer | Used in the same way as for women when HER2-positive |
| Gastric adenocarcinoma | Trastuzumab with chemotherapy for advanced HER2-positive disease |
| Oesophageal adenocarcinoma | Especially cancers at the junction with the stomach |
| Salivary duct carcinoma | Often HER2-positive; HER2 drugs used for advanced disease |
| Colorectal adenocarcinoma | Small group with HER2 amplification and no RAS mutation |
| Lung adenocarcinoma | T-DXd for cancers with HER2 mutations |
| Endometrial cancer | Some aggressive types are HER2-positive |
HER2 test results
| Result | Meaning |
|---|---|
| IHC 3+ | HER2-positive |
| IHC 2+ and ISH positive | HER2-positive |
| IHC 2+ and ISH negative, or IHC 1+ | HER2-low; T-DXd may be an option in advanced breast cancer |
| IHC 0 | HER2-negative |
Why testing matters
HER2-targeted drugs only help cancers that carry the target. Testing is therefore essential, and sometimes a second biopsy is advised if cancer comes back, because HER2 status can change over time. Stomach cancers can be patchy, so several samples may be needed to give an accurate result.
4. Before treatment
| Step | Why it is done |
|---|---|
| HER2 testing | Confirms the cancer will respond |
| Heart scan | Checks the pumping function (ejection fraction) before starting |
| Blood tests | Blood counts, liver and kidney function |
| Chest scan or lung history | Important before T-DXd |
| Pregnancy test | HER2 antibodies can harm a developing baby |
| Line or port | Sometimes inserted if many drips are needed |
5. What to expect: step by step
Early breast cancer
| Step | What happens |
|---|---|
| 1. Treatment before surgery | Chemotherapy with trastuzumab and pertuzumab for several months |
| 2. Surgery | Removes the remaining tumour |
| 3. Assessing response | The pathologist checks whether any cancer is left |
| 4. Treatment after surgery | Trastuzumab (with or without pertuzumab) to complete a year; T-DM1 if cancer remained |
| 5. Radiotherapy and hormone therapy | Added when appropriate |
Each treatment visit
| Step | What happens |
|---|---|
| 1. Check-in | Weight, blood pressure and symptom review |
| 2. Drug given | First dose takes longer (about 90 minutes); later doses are quicker |
| 3. Observation | Watched for reactions, especially after the first dose |
| 4. Home | Most people go home the same day |
Trastuzumab and pertuzumab can also be given as an injection under the skin of the thigh, taking only a few minutes.
6. Side effects and risks
| Side effect | Most associated with | Notes |
|---|---|---|
| Reduced heart pumping function | Trastuzumab, pertuzumab | Usually reversible; monitored with heart scans |
| Infusion reactions | Antibodies | Fever, chills, mostly with the first dose |
| Diarrhoea | Pertuzumab, neratinib, tucatinib | Often manageable with medicines |
| Lung inflammation (interstitial lung disease) | T-DXd | Report cough or breathlessness straight away |
| Nausea and tiredness | T-DXd, T-DM1 | Anti-sickness medicines help |
| Low platelets and liver changes | T-DM1 | Monitored with blood tests |
| Hair loss | T-DXd; chemotherapy partners | Not usually from trastuzumab alone |
| Rash | Pertuzumab, tablets | Usually mild |
In the DESTINY-Breast03 trial, drug-related lung inflammation affected about 15% of people given T-DXd, with no life-threatening cases (Hurvitz et al., 2023). In HERA, heart problems were uncommon and mostly occurred during treatment (Cameron et al., 2017).
7. Results and outlook
| Study | Main finding |
|---|---|
| HERA, early breast cancer | One year of trastuzumab after chemotherapy reduced the risk of cancer returning and death; two years gave no extra benefit (Cameron et al., 2017) |
| CLEOPATRA, advanced breast cancer | Adding pertuzumab to trastuzumab and docetaxel raised median survival from about 41 to 57 months (Swain et al., 2020) |
| DESTINY-Breast03, advanced breast cancer | T-DXd controlled cancer for a median of about 29 months versus about 7 months with T-DM1, and improved survival (Hurvitz et al., 2023) |
| DESTINY-Breast04, HER2-low breast cancer | T-DXd roughly doubled the time to progression compared with chemotherapy and improved survival (Modi et al., 2022) |
| ToGA, stomach and gastro-oesophageal cancer | Adding trastuzumab to chemotherapy improved median survival from about 11 to almost 14 months (Bang et al., 2010) |
HER2-low: a new category
For many years, breast cancers were simply HER2-positive or HER2-negative. The DESTINY-Breast04 trial showed that cancers with only low levels of HER2 could also benefit from T-DXd. This has changed how pathologists report HER2 tests, and many more people with advanced breast cancer now have this option.
8. Recovery and aftercare
During treatment
| Tip | Why |
|---|---|
| Keep heart scan appointments | Early changes can be managed by pausing treatment |
| Report breathlessness or swollen ankles | Possible signs of heart strain |
| Report new cough or breathlessness on T-DXd | Lung inflammation needs prompt treatment |
| Use contraception | Continue for several months after the last dose |
| Stay active | Helps energy levels and heart health |
After treatment
| Check | Purpose |
|---|---|
| Regular follow-up | Check for recurrence and late effects |
| Mammograms | For people treated for breast cancer |
| Heart health | Blood pressure, cholesterol and a healthy lifestyle |
Coping with a long course
A year of treatment every three weeks can feel long, especially after the more intense chemotherapy phase has ended. Many people find the maintenance phase easier, with fewer side effects and more time to return to usual activities. Your breast care nurse or specialist nurse can help with practical and emotional concerns along the way.
Working and daily life
Most people can carry on with many normal activities during maintenance trastuzumab, which has fewer side effects than chemotherapy. Some people continue working, perhaps with adjusted hours on treatment days. Talk to your employer about flexible arrangements if needed.
Combining with other treatments
HER2-positive cancers that are also hormone receptor-positive are treated with hormone therapy too. In some advanced cancers, HER2 drugs may be combined with immune checkpoint inhibitors, for example in HER2-positive stomach cancer.
Fertility and pregnancy
HER2 antibodies can reduce the fluid around a baby in the womb, so pregnancy should be avoided during treatment and for several months afterwards. If you may want children in the future, ask about fertility preservation before chemotherapy starts. Breastfeeding is not advised during treatment.
Brain metastases
HER2-positive breast cancer has a higher tendency than some other types to spread to the brain. Large antibodies cross into the brain poorly, but some tablets and conjugates can reach brain deposits. Treatment may combine these drugs with surgery or radiotherapy to the brain.
9. Alternatives
| Alternative | When it is considered |
|---|---|
| Chemotherapy alone | If HER2-targeted drugs cannot be given, such as with severe heart problems |
| Hormone therapy | For hormone receptor-positive cancers, often alongside HER2 drugs |
| Kinase inhibitor tablets | Tucatinib combinations, especially with brain metastases |
| Clinical trials | New antibodies and conjugates |
Biosimilars
The patents on trastuzumab have expired, and several biosimilar versions are now used in many countries. These are made to match the original antibody closely and go through careful testing before approval. Using them has lowered costs and widened access to treatment.
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is trastuzumab chemotherapy? | No, it is an antibody, but it is often given alongside chemotherapy |
| Will my hair fall out? | Not from trastuzumab alone; chemotherapy partners and T-DXd can cause hair loss |
| Are biosimilars as good? | Approved biosimilar versions of trastuzumab work in the same way |
| Will my heart recover? | Heart changes usually improve after pausing or stopping treatment |
| Can I have vaccines? | Most inactivated vaccines are fine; check live vaccines with your team |
| Can I drive home after treatment? | Usually yes, unless you had a reaction or were given a sedating medicine |
| How long will I be treated? | About a year for early breast cancer; longer for advanced cancer |
11. Questions to ask your care team
- What was my HER2 test result, and what does it mean?
- Which HER2 drugs do you recommend, and why?
- Can I have treatment as an injection under the skin?
- How will you check my heart during treatment?
- What side effects should I report straight away?
- Will I also need chemotherapy, hormone therapy or radiotherapy?
- Are there clinical trials I could join?
Resources
- Bang, Y.J. et al. (2010) ‘Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial’, The Lancet, 376(9742), pp. 687-697.
- Cameron, D. et al. (2017) ’11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial’, The Lancet, 389(10075), pp. 1195-1205.
- Hurvitz, S.A. et al. (2023) ‘Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial’, The Lancet, 401(10371), pp. 105-117.
- Modi, S. et al. (2022) ‘Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer’, New England Journal of Medicine, 387(1), pp. 9-20.
- Swain, S.M. et al. (2020) ‘Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study’, The Lancet Oncology, 21(4), pp. 519-530.
- National Cancer Institute (2026) Breast Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/breast/hp/breast-treatment-pdq (Accessed: October 2026).
- National Cancer Institute (2026) Trastuzumab. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/trastuzumab (Accessed: October 2026).
Prepared by the editorial team, October 2026.